For US Healthcare Professionals

Chronic Hemolysis has a central role in PNH.
SOLIRIS has a proven safety and tolerability profile
PNH? How do patients present?
Essential resources for SOLIRIS prescribers

SOLIRIS is the first and only FDA-approved treatment for PNH

SOLIRIS® (eculizumab) is indicated to reduce chronic hemolysis in patients with PNH (paroxysmal nocturnal hemoglobinuria).

Chronic hemolysis is central to the morbidities and mortality in PNH, including severe anemia, disabling fatigue, recurrent pain, dyspnea, smooth muscle dystonias, impaired quality of life and thrombotic events.1-5 More

SOLIRIS is a humanized monoclonal antibody that targets the underlying cause of chronic hemolysis — terminal complement activation.6-9

SOLIRIS has been shown to significantly reduce hemolysis in all patients with PNH, resulting in marked improvement in patient-related symptoms. Learn more about SOLIRIS


Provide your PNH patients ongoing, personalized treatment support and access to therapy with SOLIRIS OneSource. Call 1.888.SOLIRIS (1.888.765.4747) to learn more.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709.
2. Johnson RJ, Hillmen P. Paroxysmal nocturnal hemoglobinuria: nature's gene therapy? J Clin Pathol Mol Pathol. 2992;55:145-152.
3. Rosse WF, Hillmen P, Schrieber AD. Immune-mediated hemolytic anemia. Hematology. (Am Soc Hematol Educ Program) January 2004:48-62.
4. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, Benz EJ, Shattil SJ, et al. eds. Hematology. 4th ed. Philadelphia, PA: Elsevier Churchill Livingstone. 2005:419-427.
5. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. JAMA. 2005;293:1653-1662.
6. SOLIRIS prescribing information. Alexion Pharmaceuticals, Inc. 2007.
7. Data on File. Alexion Pharmaceuticals, Inc.
8. Hill A, Hillmen P, Richards S, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559-2565.
9. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. NEJM. 2006;355:1233-1243.